AIM ImmunoTech (NYSEAMERICAN:AIM) Lowered to “Hold” Rating by Zacks Research

AIM ImmunoTech (NYSEAMERICAN:AIM) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Separately, Maxim Group upgraded AIM ImmunoTech to a “strong-buy” rating in a report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $450.00.

AIM ImmunoTech Price Performance

Shares of AIM stock opened at $1.38 on Monday. AIM ImmunoTech has a 1-year low of $1.26 and a 1-year high of $36.00. The firm has a market cap of $3.92 million, a PE ratio of -0.07 and a beta of 1.19. The company has a 50-day moving average of $2.13 and a two-hundred day moving average of $4.80.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its quarterly earnings data on Monday, November 17th. The company reported ($1.57) EPS for the quarter. AIM ImmunoTech had a negative return on equity of 1,586.23% and a negative net margin of 14,062.50%.The company had revenue of $0.03 million during the quarter. Sell-side analysts anticipate that AIM ImmunoTech will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Sabby Management LLC purchased a new stake in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 28,855 shares of the company’s stock, valued at approximately $79,000. AIM ImmunoTech makes up about 0.1% of Sabby Management LLC’s holdings, making the stock its 22nd largest position. Sabby Management LLC owned about 1.06% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is currently owned by hedge funds and other institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).